Rigorous evaluation through clinical testing is vital for advancing safe and effective therapies. Clinical trials in regenerative medicine assess how engineered tissues, cell therapies, and gene editing approaches perform in human subjects across a spectrum of conditions. These trials must balance innovation with patient safety, following tightly regulated frameworks to validate therapeutic efficacy and monitor adverse outcomes. From early-phase feasibility studies to large-scale randomized trials, each stage is shaped by complex logistics, including manufacturing standards, delivery methods, and biomarker development. Clinical trials in regenerative medicine also face unique challenges like variability in cell behavior, individualized responses, and long-term monitoring. Despite these hurdles, progress continues steadily, establishing confidence in regenerative approaches through evidence-based evaluation.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cell technologies to integrate biodesign related tissue engineering within the frame of cell based regenerative medicine: towards the preventive therapeutic and rehabilitative resources and benefits
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : In vitro evaluation of lyophilized Dedifferentiated Fat cells (DFAT) impregnated artificial dermis
Kazutaka Soejima, Nihon University, School of Medicine, Japan
Title :
Nagy Habib, Imperial College London, United Kingdom
Title :
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : The regenerative medicine of the future
Marco Polettini, DVM, Italy